survodutide vs hepatic fat — genuinely asking which matters more
Trying to settle this properly because the thread from last year went in circles. The claim: MASH matters. The counter-claim: it is measurement error. Both sides have been asserting it confidently for about 5 months without either producing anything. What would actually settle it is 13 people measuring the same thing…
not approved, descriptive posts only
This is the "correlation is mechanism" thing again. You changed three variables at once.
phase 18 data is interesting, phase 18 will be different
Yeah, glucagon co-agonism is genuinely different.
the safety profile is not just tirzepatide amplified
glucagon injection is a different vector than GLP-1
Which trial arm?
the MASH indication changes the risk calculus
Disagree. What you are describing is consistent with dual agonist, not with what you concluded.